Can nitrofurantoin (Macrobid) be used safely in a patient with an estimated glomerular filtration rate of 45 mL/min/1.73 m², and what is the appropriate dosing?

Nitrofurantoin (Macrobid) Use at GFR 45 mL/min/1.73 m²

Nitrofurantoin can be used safely and effectively in patients with a GFR of 45 mL/min/1.73 m², as this falls within the acceptable range for treatment of uncomplicated urinary tract infections.

Evidence-Based Recommendation

The FDA-approved dosing for Macrobid is 100 mg every 12 hours for 7 days, taken with food 1. While the FDA label does not explicitly address GFR cutoffs, recent evidence strongly supports use at GFR 45 mL/min/1.73 m².

Key Supporting Evidence

The most robust recent data comes from a 2018 population-based cohort study of 116,945 older patients (median age 76 years) that directly addressed this question 2. This study found:

• Nitrofurantoin was not associated with increased risk of any adverse outcomes in patients with eGFR <60 mL/min/1.73 m² 2
• Compared to trimethoprim, nitrofurantoin was associated with lower odds of hospitalization for acute kidney injury across all GFR categories, including patients with eGFR 45-59 (OR 0.62,95% CI 0.40-0.94) and even those with eGFR <30 (OR 0.45,95% CI 0.25-0.81) 2
• No increased risk of treatment failure, sepsis, or death was observed 2

Historical Context and Guideline Limitations

The KDIGO/KDOQI guidelines from 2014 do not specifically address nitrofurantoin dosing in renal impairment 3. The antimicrobial section provides guidance for other antibiotics (tetracyclines require dose reduction at GFR <45 mL/min/1.73 m², macrolides at GFR <30 mL/min/1.73 m²) but nitrofurantoin is notably absent from these tables 3.

The traditional contraindication at GFR <60 mL/min/1.73 m² stems from a 1968 study by Sachs that measured urinary drug excretion rather than urinary concentrations or clinical efficacy 4. This study had severe methodological limitations including small sample size, poorly defined renal impairment criteria, and lack of clinical endpoints 4.

Clinical Efficacy Data

A 2015 Canadian study of older women (mean age 79 years, median eGFR 38 mL/min/1.73 m²) found that while nitrofurantoin had higher treatment failure rates than ciprofloxacin, this pattern was identical in patients with normal renal function (median eGFR 69 mL/min/1.73 m²), suggesting the failures were not related to renal impairment 5.

A 2017 retrospective study of hospitalized adults with renal insufficiency (CrCl <60 mL/min) showed nitrofurantoin eradicated uropathogens in 69% of cases 6. Of the treatment failures, only 2 out of 26 patients failed due to renal insufficiency (both had CrCl <30 mL/min), while most failures were due to intrinsically resistant organisms like Proteus species 6.

Safety Considerations

At GFR 45 mL/min/1.73 m², the primary concern is therapeutic efficacy rather than toxicity 2, 6. The pharmacokinetic modeling study from 2023 demonstrated that individuals with moderate-to-severe GFR reduction have 2-3 fold higher hepatic exposure to nitrofurantoin but substantially reduced urinary concentrations 7. However, clinical studies have not demonstrated increased adverse events at this GFR level 2.

Practical Algorithm for Use

For GFR ≥45 mL/min/1.73 m²:

• Use standard dosing: 100 mg every 12 hours for 7 days with food 1
• Ensure the infection is uncomplicated cystitis (not pyelonephritis or complicated UTI) 1, 6
• Verify the organism is susceptible (avoid if Proteus, Serratia, or Pseudomonas suspected) 1, 6

For GFR 30-44 mL/min/1.73 m²:

• Can still be used based on recent evidence 2, 6
• Consider alternative agents if available and equally effective 4
• Monitor clinical response closely 6

For GFR <30 mL/min/1.73 m²:

• Efficacy becomes questionable due to inadequate urinary concentrations 6, 7
• Consider alternative antibiotics unless no other options exist 4

Common Pitfalls to Avoid

• Do not avoid nitrofurantoin solely based on the outdated GFR <60 mL/min contraindication - this cutoff lacks evidence and was revised in the 2015 Beers Criteria to GFR <30 mL/min 8, 4
• Do not use for pyelonephritis or complicated UTIs regardless of GFR - nitrofurantoin achieves therapeutic concentrations only in urine, not in renal parenchyma or bloodstream 1
• Do not prescribe for infections with Proteus, Serratia, or Pseudomonas species - these organisms are intrinsically resistant 1, 6
• Temporarily discontinue during acute illness that could precipitate acute kidney injury, as recommended for other renally excreted drugs 3, 9